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VICENTE JAVIER BENEDÍ,3 AND GEORGE A. JACOBY4
Department of Microbiology, School of Medicine, University of Seville,1 and Department of Microbiology University
Hospital V. Macarena,2 Seville, and Area of Microbiology, Department of Biology and IMEDEA (CSIC-UIB),
University of the Balearic Islands, Palma de Mallorca,3 Spain, and Veterans Affairs Medical Center,
Bedford and Lahey Clinic, Burlington, Massachusetts4
Received 9 September 1998/Returned for modification 19 January 1999/Accepted 30 April 1999
Two clinical isolates of extended-spectrum b-lactamase (ESBL)-producing Klebsiella pneumoniae were noted
to be less susceptible than expected to imipenem. Both were missing outer membrane proteins that serve as
channels for antibiotic entry. The role of b-lactamase in resistance was investigated by eliminating the original
ESBL and introducing plasmids encoding various ESBLs and AmpC b-lactamase types, by studying the effect
of an increased inoculum, and by evaluating interactions with b-lactamase inhibitors. The contribution of
porin deficiency was investigated by restoring a functional ompK36 gene on a plasmid. Plasmids encoding
AmpC-type b-lactamases provided resistance to imipenem (up to 64 mg/ml) and meropenem (up to 16 mg/ml)
in strains deficient in porins. Carbapenem resistance showed little inoculum effect, was not affected by
clavulanate but was blocked by BRL 42715, and was diminished if OmpK36 porin was restored. Plasmids
encoding TEM- and SHV-type ESBLs conferred resistance to cefepime and cefpirome, as well as to earlier
oxyimino-b-lactams. This resistance was magnified with an increased inoculum, was blocked by clavulanate,
and was also lowered by OmpK36 porin restoration. In addition, SHV-2 b-lactamase had a small effect on
carbapenem resistance (imipenem MIC, 4 mg/ml, increasing to 16 mg/ml with a higher inoculum) when porins
were absent. In K. pneumoniae porin loss can thus augment resistance provided either by TEM- or SHV-type
ESBLs or by plasmid-mediated AmpC enzymes to include the latest oxyimino-b-lactams and carbapenems.
Carbapenems are usually active against extended-spectrum
b-lactamase (ESBL)-producing Klebsiella pneumoniae strains,
including porin-deficient ones (13). The MICs of meropenem
for clinical isolates of K. pneumoniae strains that produce ES-
BLs are usually 8 to 16 lower than the MICs of imipenem (4,
27). Carbapenems are also usually active against plasmid-me-
diated AmpC-type b-lactamase-producing strains (10, 16). Imi-
penem-resistant K. pneumoniae strains that produce ACT-1
(an AmpC-type b-lactamase) (3) or ESBL SHV-2 (18) and
that are deficient in a major outer membrane protein, presum-
ably a porin, have been reported recently.
Plasmid- or chromosome-encoded carbapenemases (17) or
the association of reduced outer membrane permeability with
increased chromosomal b-lactamase production have been
shown to be the major mechanisms of resistance to carbapen-
ems in several species of enterobacteria, including Enterobacter
spp. (5, 7, 9, 29), Serratia marcescens (25, 36), Citrobacter freun-
dii (19), Providencia rettgeri (29), and Escherichia coli (6, 28).
The association of porin loss and metallo-b-lactamase produc-
tion in laboratory-constructed strains of E. coli determined
resistance to both imipenem and meropenem when a high
bacterial inoculum was used (6).
As a part of a study of resistance to expanded-spectrum
b-lactams in enterobacteria, two clinical isolates of K. pneu-
moniae that were resistant to ceftazidime (MICs, .256 mg/ml
for both strains) and that presented with reduced sensitivity to
imipenem (MICs, 2 mg/ml) have been identified. The objec-
tives of this work were to evaluate the mechanisms for the
increased MIC of imipenem for these two clinical isolates and
to evaluate the relative roles of porins and b-lactamases (both
plasmid-mediated ESBLs and plasmid-mediated AmpC-type
enzymes) in the activities of imipenem, meropenem, and ceph-
alosporins against K. pneumoniae.
(This study was presented in part in the 36th and 37th
Interscience Conferences on Antimicrobial Agents and Che-
motherapy, New Orleans, La. [20a], 15 to 18 September 1996
and Toronto, Ontario, Canada, 28 September to 1 October
1997 [21a], respectively.)
MATERIALS AND METHODS
Bacterial strains. K. pneumoniae 143098-3 was cultured from sputum at the
Massachussetts General Hospital, Boston, in December 1993. It was resistant to
ceftazidime, cefotaxime, aztreonam, cefotetan, cefoxitin, chloramphenicol, cip-
rofloxacin, gentamicin, kanamycin, sulfonamide, tetracycline, tobramycin, and
trimethoprim and had a 16-mm zone diameter around a 10-mg imipenem disk.
On isoelectric focusing (22) K. pneumoniae 143098-3 had b-lactamase bands at
pIs 5.4, 7.6, and 8.2, consistent with TEM-1, SHV-1, and SHV-5 respectively, and
could transfer a plasmid (designated pMG257) encoding the pI 5.4 and 8.2 b-
lactamases to E. coli J53 Rifr by selection with ceftazidime. Strain C1 was
obtained from strain 143098-3 after overnight growth at 43°C by replica plating
for a ceftazidime susceptible derivative. It was also cefotaxime and aztreonam
sensitive but retained the parent’s resistance to the other drugs except that the
imipenem disk diameter was 24 mm. On isoelectric focusing, b-lactamase bands
at pIs 5.4 and 7.6 were retained, but the band at pI 8.2 was no longer present,
suggesting that the putative SHV-5 enzyme was no longer expressed. Attempts to
cure the entire resistance phenotype with acridine orange, ethidium bromide,
novobiocin, or sodium dodecyl sulfate (SDS) were unsuccessful.
K. pneumoniae NEDH-1 is a urine isolate obtained at the New England
Deaconess Hospital, Boston, Mass., in August 1994. The isolate was resistant to
ceftazidime, cefotaxime, aztreonam, chloramphenicol, kanamycin, streptomycin,
sulfonamide, tobramycin, and trimethoprim and could transfer a plasmid (named
pMG258) encoding resistance to these drugs on mating to E. coli. On isoelectric
focusing, b-lactamase bands at pIs 5.4 and 7.6 consistent with TEM-1 and
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SHV-2, respectively, were present. C2 was derived from strain NEDH-1 by
growth in ethidium bromide and screening for a ceftazidime-susceptible deriva-
tive. It lost the resistance of the parent to all drugs listed above and no longer
produced b-lactamase, suggesting that pMG258 had been completely eliminated.
Plasmids coding for different TEM- or SHV-type ESBLs or AmpC-type en-
zymes were introduced by conjugation, as described previously (14), into C1 and
C2 (Table 1).
The role of porin OmpK36 expression in the resistance of b-lactam-
ase-producing strains was tested by transformation with plasmid pSHA2, which
encodes the OmpK36 porin and which contains a potassium tellurite resistance
cassette (for selection purposes) (20). Plasmid pSHA4 (which also codes for
resistance to tellurite and which is equivalent to pSHA2 but which has a trun-
cated ompK36 gene) was used as a control. Transformants were obtained on
Mueller-Hinton agar containing ceftazidime (20 mg/ml) and potassium tellurite
(30 mg/ml).
E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as
quality control strains for susceptibility testing.
Susceptibility testing. The following antimicrobial agents were tested: cefox-
itin (Sigma, Madrid, Spain), ceftazidime (Sigma), cefepime (Bristol-Myers
Squibb, Madrid, Spain), cefpirome (Hoescht Marion-Roussel, Romainville,
France), imipenem (Merck Sharpe & Dohme, Madrid, Spain), meropenem
(Zeneca Farma, Madrid, Spain), and ciprofloxacin (Sigma). All b-lactams were
tested alone or in combination with a fixed concentration (2 mg/ml) of clavulanic
acid (SmithKline Beecham, Madrid, Spain), a well-known ESBL inhibitor. The
combinations of cefoxitin, imipenem, and meropenem with the serine-b-lactam-
ase inhibitor BRL 42715 (SmithKline Beecham) were also tested against strains
that express AmpC-type enzymes. BRL 42715 is able to inhibit not only class A
b-lactamases but also class C enzymes, and for this reason it was expected that
it would inhibit the plasmid-mediated AmpC-type enzymes evaluated in the
present study. MICs were determined in cation-adjusted Mueller-Hinton broth,
according to the guidelines of the National Committee for Clinical Laboratory
Standards (23). The activities of cefepime, cefpirome, imipenem, and mero-
penem were compared at inocula of 105 and 107 CFU/ml. The E test was also
used for some assays. Media were supplemented with potassium tellurite (30
mg/ml) when strains carrying pSHA plasmids were studied in order to avoid
plasmid loss.
Isoelectric focusing of b-lactamases. Cells were grown to the logarithmic
phase and were disrupted by sonication. After removal of nonbroken cells and
debris, the supernatant was used to determine pIs by isoelectric focusing as
described previously (20, 22). b-Lactamases with known pIs (TEM-1, pI 5.4;
TEM-3, pI 6.3; TEM-4, pI 5.9; TEM-26, pI 5.6; SHV-3, pI 7.0; SHV-2, pI 7.6; and
SHV-5, pI 8.2) were used for comparison.
Isolation and analysis of OMPs. Outer membrane proteins (OMPs) were
isolated as sodium lauryl sarcosinate (2%)-insoluble material from cell envelopes
obtained by sonication of bacteria grown in nutrient broth (8). Electrophoretic
analysis of OMPs was performed by SDS-polyacrylamide gel electrophoresis
(PAGE) as described elsewhere (15, 20).
DNA manipulations. Plasmids pSHA2 and pSHA4 were transformed into the
desired strains by electroporation. Standard procedures for agarose gel electro-
phoresis and plasmid transformation were used (32).
RESULTS
K. pneumoniae C1 and C2 were deficient in both OmpK35
and OmpK36 porins, as determined by SDS-PAGE (data not
shown). Tables 2 and 3 show that introduction of TEM- or
SHV-type ESBLs into these strains increased the MICs of
TABLE 1. Plasmids used in the study
Plasmid Enzyme Origin Reference
pMG226 TEM-6 Munich, Germany 2, 11
pMG223 TEM-10 Boston, Mass. 11, 31
pMG224 TEM-12 Cambridge, Mass. 30, 31
pMG225 TEM-26 Cambridge, Mass. 30, 31
pMG229 SHV-2 Paris, France 11, 13
pMG258 SHV-2a Boston, Mass. This paper
pDU18 SHV-3 Paris, France 24
pMG257 SHV-5a Boston, Mass. This paper
pMG233 AmpCb Providence, R.I. 26
pMG245 AmpCb Boston, Mass. 12
pMG248 AmpCc Durham, N.C. 12
pMG250 AmpCd Ann Arbor, Mich. 12
pMG252 AmpCe Birmingham, Ala. 21
a Presumptive identification based on pI determination.
b Enterobacter cloacae type.
c Sequence not yet analyzed.
d C. freundii type.
e Related to the group of AmpC-type b-lactamases distantly related to the
chromosomal enzyme of P. aeruginosa.
TABLE 2. MICs of antimicrobial agents determined by microdilution for ESBL- or AmpC-producing strains
of K. pneumoniae at an inoculum of 105 or 107 CFU/ml
Strain Plasmid Enzyme
MIC (mg/ml) at the indicated inoculum (CFU/ml)a:
FOX, 105
FEP PIR IPM MEM
CIP, 105
105 107 105 107 105 107 105 107
143098-3b pMG257 SHV-5 64 128 .256 128 .256 2 2 2 2 8
C1 No ESBL 128 1 2 0.5 2 1 1 1 1 8
C1-T6 pMG226 TEM-6 128 32 .256 64 .256 1 2 1 2 8
C1-T10 pMG223 TEM-10 64 8 .256 32 .256 1 4 2 1 8
C1-T12 pMG224 TEM-12 128 64 .256 128 .256 1 1 1 1 8
C1-T26 pMG225 TEM-26 128 16 .256 32 .256 1 2 1 2 8
C1-S2 pMG229 SHV-2 128 .256 .256 256 .256 4 16 4 4 8
C1-S3 pUD18 SHV-3 128 16 .256 16 .256 2 2 2 2 4
C1-S5 pMG257 SHV-5c 64 128 .256 128 .256 2 2 2 2 8
C1-AC233 pMG233 AmpC .256 1 .256 4 8 64 64 16 16 8
C1-AC245 pMG245 AmpC .256 1 .256 4 32 32 64 16 16 4
C1-AC248 pMG248 AmpC .256 2 .256 8 .256 32 64 4 16 8
C1-AC252 pMG252 AmpC .256 2 32 16 .256 1 2 2 4 32
NEDH-1d pMG258 SHV-2 64 .256 .256 .256 .256 2 2 2 2 0.5
C2 No ESBL 64 0.25 #0.5 0.5 0.5 1 2 0.25 1 0.5
C2-S2 pMG258 SHV-2c 64 .256 .256 .256 .256 2 2 1 2 0.5
C2-AC248 pMG248 AmpC .256 8 32 64 128 64 64 16 16 0.5
C2-AC250 pMG250 AmpC .256 2 16 16 32 16 32 4 8 0.5
C2-AC252 pMG252 AmpC .256 4 .32 32 .32 0.5 2 0.5 2 4
a Abbreviations: FOX, cefoxitin; IPM, imipenem; MEM, meropenem; FEP, cefepime; PIR, cefpirome; CIP, ciprofloxacin.
b Parental strain of strain C1.
c Presumptive identification based on pI.
d Parental strain of strain C2.
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ceftazidime, cefepime, and cefpirome but not that of cefoxitin.
The MICs of imipenem and meropenem were not increased
except for a fourfold increase with the SHV-2 b-lactamase.
Introduction of plasmids encoding AmpC-type b-lactamases
also increased the MICs of cefepime and cefpirome, but to a
lesser extent, especially for cefepime. Cefoxitin MICs were
higher by acquisition of AmpC-type enzymes, and all except
the enzyme determined by pMG252 increased imipenem MICs
as much as 64-fold and meropenem MICs up to 16-fold.
Table 2 shows that increasing the test inoculum from 105 to
107 CFU/ml resulted in higher MICs of cefepime and cefpi-
rome for both ESBL- and AmpC-producing strains. The higher
inoculum did not enhance the carbapenem resistance of the
ESBL-producing strains except for those with SHV-2, for
which the imipenem MIC reached 16 mg/ml. With AmpC
strains carbapenem resistance showed a two- to fourfold inoc-
ulum effect, with MICs of 64 mg/ml for imipenem and 16 mg/ml
for meropenem.
Clavulanic acid blocked resistance to ceftazidime, cefepime,
and cefpirome produced by TEM- and SHV-type ESBLs in
strains C1 and C2 (Table 3). The resistance to cefoxitin, imi-
penem, and meropenem produced by AmpC-type b-lactam-
ases was reduced by BRL 42715 but not by clavulanic acid
(Table 3).
SDS-PAGE analysis documented that the missing OmpK36
porin was restored by transformation with plasmid pSHA2.
Control strains transformed with plasmid pSHA4 (which en-
codes a truncated ompK36 gene) remained OmpK36 deficient
(data not shown). Table 4 shows that restoration of OmpK36
lowered the MICs of ceftazidime, cefoxitin, cefepime, and cef-
pirome and, for AmpC-producing strains, the MICs of imi-
penem and meropenem. The MICs of imipenem (32 to 64
mg/ml) and meropenem (16 mg/ml) were reduced to 0.5 to 2
and 0.25 mg/ml, respectively, by a functional OmpK36 porin.
The MICs of cefoxitin, imipenem, and meropenem in the pres-
ence of BRL 42715 for strain C1-AC248 that expressed or that
did not express porin OmpK36 were 4 and 128 mg/ml, respec-
tively, for cefoxitin, 1 and 1 mg/ml, respectively, for imipenem,
TABLE 3. MICs of cephalosporins and carbapenems alone and combined with clavulanic acid or BRL 42715 for
K. pneumoniae strains producing different b-lactamases
Strain Enzyme
MIC (mg/ml) with the indicated inhibitora:
CAZ FEP PIR FOX IMP MEM
NI CLA NI CLA NI CLA NI CLA BRL NI CLA BRL NI CLA BRL
143098-3 SHV-5b .256 #0.5 128 ND 128 ND 64 64 64 2 1 1 2 2 2
C1 No ESBL 2 #0.5 1 1 #0.5 1 128 64 64 1 0.5 0.5 1 1 2
C1-T6 TEM-6 .256 #0.5 32 1 64 1 128 64 ND 1 1 ND 1 1 ND
C1-T10 TEM-10 128 1 8 2 32 4 64 64 ND 1 0.5 ND 2 1 ND
C1-T12 TEM-12 .256 8 64 1 128 2 128 128 ND 1 1 ND 1 1 ND
C1-T26 TEM-26 .256 #0.5 16 1 32 2 128 128 ND 1 1 ND 1 1 ND
C1-S2 SHV-2 .256 #0.5 .256 16 256 16 128 128 ND 4 4 ND 4 4 ND
C1-S3 SHV-3 .256 8 16 2 16 2 128 64 ND 2 1 ND 2 1 ND
C1-S5 SHV-5 .256 #0.5 128 2 128 4 64 64 64 2 1 1 2 2 2
C1-AC233 AmpC 64 64 1 0.5 4 2 .1,024 .1,024 64 64 32 1 16 8 2
C1-AC245 AmpC 128 128 1 0.5 4 2 .1,024 .1,024 64 64 32 4 16 8 2
C1-AC248 AmpC 128 64 2 1 8 4 .1,024 .1,024 128 32 16 2 4 4 2
C1-AC252 AmpC 256 128 2 1 16 8 .1,024 .1,024 64 1 1 0.5 2 4 2
NEDH-1 SHV-2 .256 2 .256 ND .256 ND 64 64 64 2 0.5 1 2 2 1
C2 Cured #0.5 #0.5 #0.5 #0.5 #0.5 #0.5 64 32 32 1 0.5 0.5 0.25 0.5 0.5
C2-S2 SHV-2 .256 4 .256 #0.5 .256 2 64 32 ND 2 1 ND 1 0.5 ND
a Abbreviations: CAZ, ceftazidime; PIM, cefepime; PIR, cefpirome; FOX, cefoxitin; IPM, imipenem; MEM, meropenem; CLA, clavulanic acid; BRL, BRL 42715;
NI, no inhibitor; ND, not determined.
b Presumptive identification based on pI determination.
TABLE 4. MICs of antimicrobial agents for K. pneumoniae strains that produce different ESBLs and
that express or do not express OmpK36 porin
Strain Enzyme
MIC (mg/ml)a

























C1 No ESBL 4 .256 1 3 0.125 0.5 0.094 0.125 1.5 1.5 ND ND
C1-T6 TEM-6 8 .256 32 .256 4 32 3 64 1.5 1.5 ND ND
C1-T12 TEM-12 12 .256 .256 .256 4 64 0.5 64 1 1 ND ND
C1-T26 TEM-26 8 .256 .256 .256 1.5 8 1 16 1 1 ND ND
C1-S2 SHV-2 16 .256 .256 .256 6 .256 4 64 3 4 ND ND
C1-S3 SHV-3 4 192 .256 .256 0.5 16 0.75 32 1.5 2 ND ND
C1-S5 SHV-5 8 96 .256 .256 3 64 1 64 2 2 ND ND
C1-AC248 AmpC 64 .256 64 128 0.25 1 1 4 2 32 0.25 16
C2-AC248 AmpC 128 .256 256 .256 1 4 2 16 0.5 64 0.25 16
a MICs were determined with E-test strips. OmpK36(1), OmpK36 porin expression; OmpK36(2), OmpK36 porin nonexpression; ND, not determined. Antibiotic
abbreviations are as in footnotes a of Tables 2 and 3.
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and 0.25 and 4 mg/ml, respectively, for meropenem. The cor-
responding values for strain C2-AC248 that expressed or that
did not express OmpK36 were 4 and 64 mg/ml, respectively, for
cefoxitin, 0.125 and 0.25 mg/ml, respectively, for imipenem, and
0.03 and 0.25 mg/ml, respectively, for meropenem.
DISCUSSION
Results from this study confirm previous observations (20,
35) indicating that resistance to expanded-spectrum cephalo-
sporins increases in K. pneumoniae strains that produce TEM-
or SHV-type ESBLs that lack the two major porins of the
species (OmpK35 and OmpK36). The level of resistance fur-
ther increased when a high inoculum (107 CFU/ml) was used,
and this may be clinically relevant in situations in which the
number of bacteria at the site of infection is particularly high.
Restoration of OmpK36 function in porin-deficient strains
producing ESBLs caused significant decreases in the MICs of
ceftazidime, cefepime, and cefpirome. In E. coli we have ob-
served that the expression of OmpF in strains that are deficient
in both OmpF and OmpC porins and that hyperproduce chro-
mosomal b-lactamase is more efficient than expression of
OmpC in reverting the resistant phenotype (28). It has been
previously shown that the OmpK36 porin of K. pneumoniae is
homologous to OmpC of E. coli (1). Cloning of the ompK35
gene of K. pneumoniae is in progress and will allow evaluation
of the role of this other porin, in comparison with that of
OmpK36, in the resistance of K. pneumoniae to antimicrobial
agents.
ESBL production did not affect the activities of carbapen-
ems except when imipenem was tested against strain C1-S2
(which produces SHV-2), for which MICs of 4 mg/ml (105
cfu/ml) and 16 mg/ml (107 cfu/ml) were obtained. It has previ-
ously been reported that a clinical isolate of K. pneumoniae
that produces SHV-2 was resistant to imipenem (MIC, 8 mg/
ml) and meropenem (MIC, 16 mg/ml) (18).
The expression of AmpC-type enzymes affected the activities
of cefoxitin (which is in contrast to the effects of ESBLs) and
ceftazidime, as has been shown for other plasmid-mediated
AmpC-type b-lactamases (10, 16). On the other hand, only
moderate increases were observed when cefepime or cefpi-
rome were tested, with cefepime MICs being two to eight times
lower than those of cefpirome. The relative better activities of
both cefepime and cefpirome in comparison with those of
older cephalosporin derivatives relates to their increased sta-
bility to chromosomal AmpC enzymes (from which plasmid-
mediated AmpC-type enzymes have been shown to be derived)
and to their relatively higher level of permeation through the
outer membranes of gram-negative bacteria (33). These data
suggest that cefepime and cefpirome could represent thera-
peutic alternatives against AmpC-type producing organisms
resistant to multiple antimicrobial agents, as has already been
shown for infections caused by ceftazidime-resistant Enter-
obacter (34). Caution is suggested, however, from the signifi-
cant increases in the MICs of both cefepime and cefpirome
when a high inoculum was used in the susceptibility assay.
The production of AmpC-type enzymes significantly in-
creased the MICs of carbapenems, in agreement with the re-
port by Bradford et al. (3) with the ACT-1 b-lactamase. BRL
42715 was able to revert the resistance conferred by AmpC-
type enzymes, as expected for class C-related b-lactamases
(16). Although BRL 42715 is not available for clinical use, it
would be interesting to develop compounds with activity sim-
ilar to that of BRL 42715 to assess their therapeutic potential.
Resistance to carbapenems also depends on the absence of
porins, because restoration of OmpK36 significantly reduced
the level of resistance. The results obtained after simultaneous
inhibition of the AmpC enzyme and expression of OmpK36 in
strains C1-AC248 and C2-AC248 suggest that b-lactamase
production is the most important factor for resistance to imi-
penem, while loss of porins seems more important or as im-
portant for resistance to meropenem.
The apparent existence of different mechanisms of resis-
tance to imipenem and meropenem in K. pneumoniae is also
supported by the observation that inhibition of the AmpC
enzymes of strains C1-AC248 and C2-AC248 with the same
amount of BRL 42715 resulted in a larger decrease in the
MICs of imipenem for C2-AC248 than for C1-AC248. Simi-
larly, although both strains present similar levels of resistance
to meropenem, the decrease in the MIC of this agent in the
presence of BRL 42715 was also higher for strain C2-AC248. It
is unlikely that this was caused by a poorer inhibition of the
enzyme in strain C1-AC248, because an increase in the con-
centration of BRL 42715 to 16 mg/ml did not result in an
additional decrease in the MIC of either imipenem or mero-
penem (data not shown).
Although the main objective of this study was to evaluate the
mechanisms that lead to resistance to carbapenems and ceph-
alosporins in K. pneumoniae, ciprofloxacin was also included as
a control for experiments on OmpK36 expression, because its
activity is slightly increased when this porin is produced (20)
and possible interactions between b-lactamase expression and
fluoroquinolone activity were of interest. Surprisingly, one of
the plasmids coding for an AmpC-type enzyme (pMG252) was
able to increase the resistance to ciprofloxacin in the two K.
pneumoniae strains evaluated. Details about this finding have
been published elsewhere (21). It is noteworthy that pMG252
was the only plasmid of those evaluated in the present study
that codes for an enzyme that determined resistance to cefox-
itin but not to carbapenems. The AmpC-type enzyme encoded
by this plasmid belongs to the group of plasmid-mediated
AmpC-type b-lactamases (CMY-1, FOX-1, MOX-1, and oth-
ers) distantly related to the chromosomal enzyme of P. aerugi-
nosa (unpublished data). More enzymes of this type need to be
tested to determine if this is a general and potentially distin-
guishing property of this class of enzymes.
Plasmid-mediated AmpC-type enzymes have increasingly
been recognized in recent years. Data from previous reports
and from this work suggest that these bacterial enzymes may
represent a new threat against the more recently introduced
antimicrobial agents. The spread of strains that lack porins and
that express these new plasmid-mediated enzymes may create
serious therapeutic problems in the future.
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